Investors bought shares of SAGE Therapeutics Inc (NASDAQ:SAGE) on weakness during trading hours on Friday. $160.55 million flowed into the stock on the tick-up and $120.98 million flowed out of the stock on the tick-down, for a money net flow of $39.57 million into the stock. Of all equities tracked, SAGE Therapeutics had the 11th highest net in-flow for the day. SAGE Therapeutics traded down ($13.90) for the day and closed at $152.15

SAGE has been the topic of a number of research reports. Royal Bank of Canada reduced their target price on shares of SAGE Therapeutics from $145.00 to $137.00 and set an “outperform” rating on the stock in a report on Monday, November 27th. SunTrust Banks set a $82.00 target price on shares of SAGE Therapeutics and gave the stock a “buy” rating in a report on Thursday, October 19th. BMO Capital Markets restated a “buy” rating and issued a $80.00 target price on shares of SAGE Therapeutics in a report on Friday, October 27th. Chardan Capital upgraded shares of SAGE Therapeutics from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $60.00 to $140.00 in a report on Friday, November 10th. Finally, JPMorgan Chase & Co. restated a “buy” rating on shares of SAGE Therapeutics in a report on Wednesday, January 10th. One analyst has rated the stock with a sell rating, three have given a hold rating and twelve have given a buy rating to the stock. SAGE Therapeutics currently has an average rating of “Buy” and an average price target of $171.21.

In related news, insider Albert Robichaud sold 60,000 shares of the company’s stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $159.43, for a total transaction of $9,565,800.00. Following the transaction, the insider now directly owns 152,759 shares in the company, valued at approximately $24,354,367.37. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jeffrey M. Jonas sold 210,247 shares of the company’s stock in a transaction dated Thursday, December 21st. The shares were sold at an average price of $157.45, for a total transaction of $33,103,390.15. Following the transaction, the chief executive officer now owns 211,473 shares in the company, valued at $33,296,423.85. The disclosure for this sale can be found here. Insiders have sold a total of 314,247 shares of company stock worth $50,465,110 over the last quarter. 6.10% of the stock is currently owned by insiders.

A number of large investors have recently modified their holdings of the stock. Ameritas Investment Partners Inc. grew its holdings in SAGE Therapeutics by 19.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,034 shares of the biopharmaceutical company’s stock valued at $242,000 after purchasing an additional 497 shares during the last quarter. Ameriprise Financial Inc. grew its holdings in SAGE Therapeutics by 0.9% during the 2nd quarter. Ameriprise Financial Inc. now owns 59,336 shares of the biopharmaceutical company’s stock valued at $4,723,000 after purchasing an additional 552 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in SAGE Therapeutics by 50.8% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,078 shares of the biopharmaceutical company’s stock worth $342,000 after acquiring an additional 700 shares in the last quarter. Fortaleza Asset Management Inc. bought a new position in SAGE Therapeutics in the 4th quarter worth about $167,000. Finally, First Mercantile Trust Co. bought a new position in SAGE Therapeutics in the 4th quarter worth about $169,000. Institutional investors own 95.01% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Traders Buy SAGE Therapeutics (SAGE) on Weakness” was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://theolympiareport.com/2018/02/11/traders-buy-sage-therapeutics-sage-on-weakness.html.

About SAGE Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.